Advanced search
Publication Cover
Current Medical Research and Opinion Volume 31, 2015 - Issue 7
Submit an article Journal homepage
1,464
Views
11
CrossRef citations to date
0
Altmetric
Editorial

Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points

Daisuke YabeCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan;Center for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, Osaka, Japan;Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, JapanCorrespondence[email protected] [email protected]
,
Hitoshi KuwataCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan
,
Ryota UsuiCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan
,
Takeshi KuroseCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan
&
Yutaka SeinoCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, JapanCorrespondence[email protected] [email protected]
Pages 1267-1270 | Accepted 17 Apr 2015, Published online: 20 May 2015

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Chen-Hsiu Lin, Li Shao, Yu-Mei Zhang, Yu-Ju Tu, Yuzhen Zhang, Brian Tomlinson, Paul Chan & Zhongmin Liu. (2020) An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy 21:3, pages 275-285.
Read now
Awadhesh Kumar Singh & Ritu Singh. (2017) Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Expert Review of Clinical Pharmacology 10:6, pages 633-647.
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs 25:10, pages 1167-1179.
Read now
André J. Scheen. (2016) Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Review of Clinical Pharmacology 9:3, pages 385-399.
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 25:2, pages 145-158.
Read now
Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel & Gary Meininger. (2015) Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion 31:11, pages 1993-2000.
Read now

Articles from other publishers (4)

C.C. Berra, V. Resi, M. Mirani, L. Folini, A. Rossi, S.B. Solerte & P. Fiorina. (2020) Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes. Pharmacological Research 159, pages 104996.
Crossref
Ruth E. Brown, Alexander Abitbol, Harpreet S. Bajaj, Ronald Goldenberg, Hasnain Khandwala, Suzan Abdel-Salam & Ronnie Aronson. (2019) Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study. Diabetes Research and Clinical Practice 156, pages 107820.
Crossref
Steve Kanters, Lars Wilkinson, Hrvoje Vrazic, Rohini Sharma, Sandra Lopes, Evan Popoff & Eric Druyts. (2019) Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. BMJ Open 9:7, pages e023458.
Crossref
Yutaka Seino, Daisuke Yabe, Takashi Sasaki, Atsushi Fukatsu, Hisae Imazeki, Hidekazu Ochiai & Soichi Sakai. (2017) Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study. Journal of Diabetes Investigation 9:2, pages 332-340.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.